pantoprazole

Proton Pump Inhibitor-Associated Restless Legs Syndrome.

Leonard Susan D SD, Bui Albert K AK

Proton pump inhibitors (PPIs) are among the most commonly prescribed medications worldwide and are generally well tolerated. Although gastrointestinal adverse effects are well recognized, sleep-related adverse effects are considered uncommon and remain underrecognized. We present the case of a 41-year-old man who developed restless legs syndrome resulting in significant sleep disturbance shortly after initiation of pantoprazole therapy for nonsteroidal anti-inflammatory drug (NSAID)-induced duodenal ulcer bleeding. Despite empiric oral iron supplementation for suspected iron deficiency following acute gastrointestinal blood loss, his symptoms persisted throughout the eight-week course of therapy and resolved within several days after discontinuation of pantoprazole. Although iron deficiency represented an important alternative explanation, the close temporal relationship with pantoprazole therapy, lack of response to iron supplementation, and rapid symptom resolution following drug discontinuation suggest a probable medication-associated adverse effect. This case highlights an uncommon but potentially reversible adverse drug reaction and reinforces the importance of considering PPIs in the differential diagnosis of new-onset restless legs syndrome or sleep disturbances after initiation of therapy.

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients.

Christensen Louise Westberg Strejby LWS, Boas Anne Kirstine AK, Clausen Emilie E, Koch Nicoline Elers NE et al.

Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug-metabolizing capacity are not routinely available. We evaluated the clinical relevance of pharmacogenomic (PGx) information for key pharmacogenes implicated in medication elimination in older adults presenting to the emergency department. Fourteen pharmacogenes were analysed using the Personal Medicine Profile™ test. GeneYouIn PillCheck™ software performed genotype-to-phenotype translations, identified drug-gene interactions (DGIs) and generated a clinical decision report based on each patient's actual medication use. Among 125 acutely admitted older medical patients (median age 78.3 years; 10 medications; 7 chronic diseases), PGx testing identified 88 DGIs across 63 patients (50.4%). Of these, 46.5% were considered by clinical experts to be clinically relevant for the individual patient, affecting 33 patients (26.4%) in the total study population. Frequently implicated pharmacogenes included CYP2C19 (25.0%), SLCO1B1 (25.0%), CYP2D6 (20.5%), CYP2C9 (14.8%) and OPRM1 (6.8%), and frequently implicated medications included losartan (13.6%), pantoprazole (12.5%), simvastatin (12.5%), atorvastatin (11.4%) and metoprolol (11.4%). With more than one-quarter of acutely admitted older medical patients having one or more clinically relevant DGIs, these findings suggest that PGx information may have meaningful clinical utility for improving prescribing practices in acute care. However, interpretation in this population requires careful consideration of other factors such as nutritional status and inflammation that may modify pharmacogene activity.

Pantoprazole and other proton pump inhibitors, sleep, and cardiovascular safety: weak but plausible evidence.

Menezes-Rodrigues Francisco Sandro FS, Tallo Fernando Sabia FS, Herbella Fernando Augusto Mardiros FAM, Caixeta Adriano A et al.

Review of promising benzimidazole-based anticancer agents (2023-2026).

Shumilova Elena Y EY, Sysolyatin Sergey V SV, Strokova Svetlana V SV

Benzimidazoles represent a key class of heterocyclic compounds that stand out for their wide range of biological activity. This scaffold has become particularly important in medicinal chemistry due to its ability to mimic the purine bases of natural nucleosides, which ensures active interaction with biological targets. Today, the benzimidazole moiety provides a basis for many clinically significant drugs, such as omeprazole, albendazole, pantoprazole, and others. The potential of benzimidazole derivatives as inhibitors of cancer cell proliferation has actively been studied in recent years. In this regard, the development of highly selective, low-toxicity cytostatic molecules based on benzimidazole is highly relevant for modern oncopharmacology. This paper provides a systematic overview of advances reported over 2023-2026 in the anticancer activity of benzimidazole derivatives. The focus is on the results of preclinical studies on a panel of cell lines, including cervical carcinoma (HeLa), bladder carcinoma (HTB-9), non-small cell lung cancer (A-549), colorectal carcinoma (HCT-116), colon cancer (HT-29), chronic myeloid leukemia (K-562), acute lymphoblastic leukemia (CCRF-CEM), breast adenocarcinoma (MCF-7), triple-negative breast cancer (MDA-MB-231), hepatocellular carcinoma (HepG2), and glioblastoma (LN-18). The data analysis revealed the most promising compounds that exhibit a pronounced cytostatic activity against cancer cells. The relationship between the molecular structure and activity of the examined compounds was evaluated. This review summarizes the latest achievements in this field and can serve as a basis for a further search for novel benzimidazole skeleton-containing anticancer agents.